

**IN THE CLAIMS**

**This listing of the claims replaces all prior versions of the claims in the application.**

**Listing of the Claims**

1. - 20. (Canceled.)

21. (Withdrawn.) An isolated polypeptide selected from the group consisting of:

- a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-65,
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-65,
- a) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-65, and
- b) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-65.

22. (Currently amended.) An isolated polynucleotide encoding a polypeptide ~~of claim 21~~ selected from the group consisting of:

- a) a polypeptide comprising an amino acid sequence of SEQ ID NO:5,
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:5,
- c) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:5, and
- d) an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:5.

23. (Previously presented.) A recombinant polynucleotide comprising a promoter sequence operably linked to the polynucleotide of claim 22.
24. (Previously presented.) A cell transformed with the recombinant polynucleotide of claim 23.
25. (Withdrawn.) A transgenic organism comprising the recombinant polynucleotide of claim 23
26. (Currently amended..) A method of producing a polypeptide encoded by a polynucleotide of claim ~~21~~ 22, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim ~~21~~ 22, and
  - b) recovering the polypeptide so expressed.
27. (Withdrawn.) An isolated antibody which specifically binds to a polypeptide of claim 21.
28. (Withdrawn.) An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:66-69 and SEQ ID NO:71-130,
  - b) a polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:66-69 and SEQ ID NO:71-130,
  - c) a polynucleotide complementary to a polynucleotide of a),
  - d) a polynucleotide complementary to a polynucleotide of b) and
  - e) an RNA equivalent of a)-d).

29. (Currently amended.) An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO:70,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence of SEQ ID NO:70,
- c) a polynucleotide complementary to the polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b) and
- e) an RNA equivalent of a) -d).

30. (Withdrawn.) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 29, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

31. (Withdrawn.) A method of claim 30, wherein the probe comprises at least 60 contiguous nucleotides.

32. (Withdrawn.) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 29, the method comprising:

- a) amplifying said target polynucleotide using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide and optionally, if present, the amount thereof.

33. (Withdrawn.) A composition comprising the polypeptide of claim 21 and a pharmaceutically acceptable excipient.

34. (Withdrawn.) A method for treating a disease or condition associated with decreased expression of functional HTRM, comprising administering to a patient in need of such treatment the composition of claim 33.